Johnson & Johnson, Novartis and Astellas all took part in the first close of a round for oncology therapy developer 28-7 Therapeutics that now stands at $82.8m.
Milestone, a cardiovascular nasal spray developer that raised more than $167m in VC funding from investors including Novo, secured $82.5m in when it went public.
BGI's gene sequencer spinoff, MGI Tech, has secured $200m in funding from Goldstone Investment, Green Pine Capital and Orient Securities despite a reported $1bn target.
Therachon, which had raised $100m from investors including Pfizer Ventures and Novo, has agreed to be acquired by Pfizer in a deal that could potentially reach $810m.
Corporate joint venture Echo Health Ventures led a $33m funding round that will help fund the home care access platform's expansion in the US.
Bloomberg has backed Unshackled Ventures, which facilitates the launch of companies by migrants and immigrants in the US, helping it reach a $20m close for its second fund.